Navigation Links
8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma Reported Today at ASCO Annual Meeting

PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced today long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR(R) Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). This regimen was found to induce durable clinical and molecular remissions in patients with this disease. Specifically, researchers reported that patients who received a single one-week treatment of BEXXAR as monotherapy achieved estimated 8-year and 10-year overall survival (OS) rates of 86%. Additionally, 50% of patients survived without progression of disease at 8 years following therapy. For patients who achieved complete remission, the median time before their disease progressed was 9.2 years. An overall response rate and complete remission rate of 95% and 75%, respectively, were observed. These data were presented today at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois (Abstract #8033).(1)

"For years we have known that radioimmunotherapy, such as BEXXAR, is an effective treatment for patients with relapsed or refractory lymphoma. The data from this frontline study suggest that BEXXAR may also have activity when used as a frontline treatment and should be studied further in this setting. Of note, these results were achieved with BEXXAR given as a single treatment, completed within one week, which made it a convenient regimen for these patients," said Mark Kaminski, Professor of Internal Medicine and Director, Leukemia/Lymphoma Program at the University of Michigan and lead investigator of this study.

The five-year follow-up data from this study were originally reported in the New England Journal of Medicine (NEJM 352:441,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
2. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
3. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
4. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
5. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
6. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
7. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Post Your Comments:
(Date:12/15/2014)... , Dec. 15, 2014  Colorado and Washington ... legalized adult use of cannabis. Oregon , ... ended prohibition during the November 2014 elections. ... - http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits of ... and obvious benefits like the increased tax revenue for state ...
(Date:12/15/2014)... -- The Government of Ghana has endorsed a ... and Terumo BCT to respond to the emerging Ebola crisis within ... health system capacity to the citizens of Ghana ... Readiness and Resilience Initiative (GERRI) is a multi-agency effort designed to: ... possible arrival of the Ebola epidemic , Provide new blood ...
(Date:12/13/2014)... 2014  Radiologists can transmit their reports, which ... referring physicians, electronic health records (EHR) systems securely, ... That was the message behind ... at the recent Radiology Society of North America ... reports in this manner also helps referring physicians ...
Breaking Medicine Technology:CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3
... a Phase 1/2 study of perifosine in combination with ... or refractory to bortezomib , , ... Inc. (Nasdaq: KERX ) today announced data ... with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple ...
... Showed Campath May Lead to Overall Survival in Patients with ... SAN FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today ... (alemtuzumab) showed activity in high-risk chronic lymphocytic leukemia (CLL) patients ... the 50th Annual Meeting of the American Society of Hematology ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... say figures are most likely too conservative , , THURSDAY, ... at least $193 billion a year in lost earnings alone, ... and anxiety disorders that greatly limit a person,s ability to ... of any condition linked to suicidal behaviors or frequent violent ...
... Poll Finds 95% of American ... - But only half believe their kids are being exposed ... Home may be where the heart,is, but these days it,s ... Agency, the average American home generates over,20 pounds of household ...
... Inc., a privately held,ophthalmic pharmaceutical company announced today ... assess the safety and efficacy of Medidur FA ... exudative age-related macular degeneration (wet AMD)., This ... investigator,sponsored IND, will compare two doses of Medidur ...
... Md., May 8 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... the treatment of cancer, inflammation and,autoimmune diseases, today announced ... 2008., Summary of Recent Events:, -- ... phase 1 clinical trial with ...
... Ortho Organizers, Inc., a,leading manufacturer of orthodontic ... of their new premium O2 Select Orthodontic,Instruments., ... Organizers President and CEO George W. Guttroff ... with the release of O2 Select,Orthodontic Instruments. ...
... 8 Samplify Systems, Inc., a,real-time signal compression ... leading expert in computed tomography, has joined its,technical ... in the,architecture, design, and development of computed tomography ... delighted to add Carl,s knowledge of the entire ...
Cached Medicine News:Health News:Mental Illness Costs U.S. Billions in Lost Earnings 2Health News:Are You Trying to Clean Your Home ... or Kill It? 2Health News:Are You Trying to Clean Your Home ... or Kill It? 3Health News:Are You Trying to Clean Your Home ... or Kill It? 4Health News:Are You Trying to Clean Your Home ... or Kill It? 5Health News:Are You Trying to Clean Your Home ... or Kill It? 6Health News:Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R) 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 9Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2Health News:Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: